Modified Oligonucleotides for Targeted PMP22 Suppression in CMT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no cure for Charcot-Marie-Tooth Disease (CMT), and existing treatments only provide symptomatic relief, with PMP22 duplication being a significant contributor to the disease progression.
Innovation Solution
Administering oligomeric compounds comprising modified oligonucleotides that are complementary to PMP22 transcripts to inhibit their expression, thereby reducing PMP22 activity and potentially slowing the progression of CMT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oligomeric compounds comprising modified oligonucleotides are administered to inhibit PMP22 expression, then PMP22 expression is reduced and disease symptoms are ameliorated, but the complexity of the treatment increases
Solution Approach 1:
The patent uses oligomeric compounds comprising modified oligonucleotides as intermediary molecules that specifically bind to PMP22 transcripts. These compounds act as mediators between the administration system and the target PMP22 gene, enabling selective inhibition of pathological PMP22 expression while sparing normal physiological functions. The modified oligonucleotides serve as the active intermediary that bridges the gap between general oligonucleotide therapy and specific PMP22-targeted treatment.
Solution Approach 2:
The patent employs modified oligonucleotides with altered chemical parameters including modified sugar moieties (2'-O-methyl, 2'-O-ethoxy methyl), modified phosphate linkages (phosphorothioate), and varied oligonucleotide lengths (15-25 nucleotides). These parameter changes enhance the stability, binding affinity, and specificity of the oligomeric compounds for PMP22 transcripts, improving treatment efficacy while managing complexity through systematic optimization of molecular parameters.
2Measurement precision
If oligonucleotides are designed to be highly complementary to PMP22 transcripts, then inhibition specificity increases, but the risk of off-target effects increases
Solution Approach 1:
The patent designs oligomeric compounds with non-uniform local qualities along the oligonucleotide sequence. Specific regions contain modified nucleotides (2'-O-methyl, 2'-O-ethoxy methyl) while other regions use different modifications or unmodified nucleotides. This local variation in chemical properties creates zones of different binding affinities and stabilities, allowing high specificity for the target PMP22 sequence while reducing off-target binding through strategically placed modified regions that modulate overall interaction characteristics.
Solution Approach 2:
The patent uses oligonucleotides with 70-90% complementarity to PMP22 transcripts rather than perfect complementarity. This partial action approach provides sufficient specificity to target PMP22 effectively while intentionally leaving some mismatch tolerance that prevents overly strong binding to completely unrelated sequences. The modified sugar moieties and phosphate linkages compensate for the reduced complementarity by enhancing overall binding affinity and stability, achieving the right balance between specificity and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method increases compound muscle action potential, motor nerve conduction velocity, and alleviates symptoms of CMT by reducing PMP22 expression, offering a therapeutic approach to ameliorate the disease.
Implementation Method 1
a modified oligonucleotide, which comprises a nucleobase sequence that is complementary to a PMP22 transcript
Data Source
AI summary
The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.